COVID-19 nasal spray moves to Phase 2 study

Encouraging preliminary results from an ongoing phase 1 study have triggered the announcement of phase 2 studies for a first-in-class nasal spray to protect people from respiratory viral diseases such as COVID-19 and influenza.

Hunter Medical Research Institute (HMRI) and University of Newcastle respiratory researchers have played an integral role in developing the spray for Australian biotech company, Ena Respiratory.

In parallel, Ena Respiratory will partner with hVIVO (part of Open Orphan plc) to evaluate the safety and efficacy of pre-exposure INNA-051 treatment in reducing viral load of influenza in experimentally infected adult volunteers. Both studies will begin in January 2022.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Cathal Friel at American Digital Week: DiTech Media

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

When Human Challenge Studies are a better option

COVID-19 vaccine distribution has been operational on a global scale since December 2020 and infection rates have dropped in relation to the pace and extent of the roll-out. While COVID-19 vaccines have proven effective against the early viruses,

Open Orphan Plc

First-in-class, broad-spectrum nasal spray to prevent COVID-19

ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has engaged research partners PPD, Inc. and hVIVO, a division of Open Orphan, to

Open Orphan Plc

Statistics, study design & methodology

Offering unrivaled expertise in biostatistics By offering tailor made solutions with a strong focus on accuracy and quality, Venn Life Sciences clients can keep a track on timelines and costs are kept to a minimum. Their statisticians provide

Open Orphan Plc

Open Orphan swings into profit due to Covid wins

UK-based pharmaceutical company, Open Orphan reported higher profit in its six-month financial statement. Revenue grew 242% to £21.9m compared to £6.4m for the same period last year. Growth was driven by six active challenge studies in the first half